Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme

Sexually Transmitted Infections

Volumn 91, Issue 3, 2015, Pages 214-219

  Chow, Eric P F ^a,b   Read, Tim R H ^a,b   Wigan, Rebecca ^a   Donovan, Basil ^c,d   Chen, Marcus Y ^a,b   Bradshaw, Catriona S ^a,b   Fairley, Christopher K ^a,b  

^a MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d SYDNEY EYE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AUSTRALIAN; CONDYLOMA ACUMINATUM; FEMALE; HETEROSEXUAL MALE; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUALITY; VACCINATION; ADOLESCENT; AUSTRALIA; CHILD; CONDYLOMATA ACUMINATA; INCIDENCE; MALE HOMOSEXUALITY; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 84928989871     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051813     Document Type: Article

References (22)

1. Brotherton JM, Murray SL, Hall MA, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust 2013;199:614-17.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884.
4. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87:544-7.
5. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032.
6. Kirby T. Australia to be first country to vaccinate boys against HPV. Lancet Oncol 2012;13:e333.
7. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502.
8. Ball SL, Winder DM, Vaughan K, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 2011;83: 1345-50.
9. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805-14.
10. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
11. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-Analysis. Lancet Infect Dis 2012;12:781-9.
12. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009;199:919-22.
13. de Visser RO, Smith AM, Rissel CE, et al. Sex in Australia: heterosexual experience and recent heterosexual encounters among a representative sample of adults. Aust N Z J Public Health 2003;27:146-54.
14. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191(Suppl 1):S97-106.
15. Chow EP, Fehler G, Chen MY, et al. Testing commercial sex workers for sexually transmitted infections in Victoria, Australia: an evaluation of the impact of reducing the frequency of testing. PLoS ONE 2014;9:e103081.
16. Gamagedara N, Hocking JS, Law M, et al. What are seasonal and meteorological factors are associated with the number of attendees at a sexual health service? An observational study between 2002-2012. Sex Transm Infect 2014;90: 635-40.
17. Lyons A, Pitts M, Grierson J. Versatility and HIV vulnerability: patterns of insertive and receptive anal sex in a national sample of older Australian gay men. AIDS Behav 2013;17:1370-7.
18. Chow EP, Lin AC, Read TRH, et al. Ratio of anogenital warts between different anatomical sites among homosexual and heterosexual individuals in Australia, 2002-2013: implications for susceptibility of different anatomical sites to genital warts. Epidemiol Infect Published Online First: 19 Aug 2014.
19. Georgousakis M, Jayasinghe S, Brotherton J, et al. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 2012;12:627-34.
20. Korostil IA, Ali H, Guy RJ, et al. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013;40:833-5.
21. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 2010;86:181-6.
22. Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Docunment: Quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil®-November 2011. Australia: Department of Health, Australia Government, 2011.